{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-22-000013","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.038347+00:00","generated_at":"2026-06-26T01:04:05.708121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%","bullets":["Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.","Non-GAAP net income $1.32B, diluted EPS $11.49 (+16% YoY); free cash flow $1.96B.","EYLEA U.S. net sales $1.52B (+13%); Dupixent global net sales $1.81B (+43% as recorded by Sanofi).","R&D guidance raised to $3.27-$3.50B (GAAP), $2.90-$3.10B (non-GAAP); SG&A guidance unchanged.","REGEN-COV inventory write-offs $58M in COGS; $211M unrealized losses on equity securities; EUA revised."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-22-000013","json":"https://secwatch.observer/filing/0001804220-22-000013.json","markdown":"https://secwatch.observer/filing/0001804220-22-000013.md","text":"https://secwatch.observer/filing/0001804220-22-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/0001804220-22-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/regn-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:04:05.708121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}